Human VCAM-1 / CD106 Protein (His Tag)

Catalog Number: 10113-H08H

General Information

Gene Name Synonym:
CD106; INCAM-100; VCAM-1

Protein Construction:
A DNA sequence encoding the extracellular domain of human VCAM1 (NP_001069.1) (Met 1-Pro 697) was fused with a polyhistidine tag at the C-terminus.

Source: Human

Expression Host: HEK293 Cells

QC Testing

Purity: > 90 % as determined by SDS-PAGE

Endotoxin:
< 1.0 EU per μg of the protein as determined by the LAL method

Stability:
Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Phe 25

Molecular Mass:
The recombinant human VCAM1 consists of 684 amino acids and predicts a molecular mass of 76 kDa. As a result of glycosylation, rhVCAM1 migrates as an approximately 110 kDa band in SDS-PAGE under reducing conditions.

Formulation:
Lyophilized from sterile PBS, pH 7.4

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:
Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:
Detailed reconstitution instructions are sent along with the products.

Protein Description

Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4β7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.

References

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

For US Customer: Fax: 267-657-0217 Tel: 215-583-7898
Global Customer: Fax :+86-10-5862-8288 Tel:+86-400-890-9989 http://www.sinobiological.com